Roivant’s Priovant Therapeutics won U.S. FDA approval for Lisraya (brepocitinib), a once-daily oral pill targeting JAK1 and TYK2, for adults with dermatomyositis. The clearance marks the first approval tied to Roivant’s hub-and-spoke strategy using a licensed asset from Pfizer and sets up commercialization and label-expansion work for additional immunology indications. Separate coverage emphasized the market positioning: the approval gives Priovant a regulatory foothold in a rare autoimmune space dominated by long-term immunosuppression and sets expectations for further clinical development across multiple rare inflammatory disorders where pathway activity overlaps with JAK1/TYK2 biology.